Androgen Deprivation Therapy (ADT) or Hormone Therapy (HT) to treat prostate cancer is a mainstay of therapy for men with recurrent or metastatic disease. There are many side effects associated with ADT including weight gain. Weight gain, an adverse metabolic change, may contribute to cardiovascular comorbidity. A better understanding of the risk factors for weight [...]
The good news is that finally Astellas and Medivation have submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI (enzalutamide) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. As of today XTANDI is currently only approved for [...]
The standard of treatment for men who have a localized recurrence in lymph nodes (LN) after surgery is intensity modulated radiation therapy (IMRT) as well as with men who have high-risk prostate cancer which includes cancer in both the prostate and seminal vesicles (SV). As with all treatments the use of IMRT comes with many [...]
Some of my posts over the last week or two have discussed the issue of the development of cross-resistance of two of our newest treatments for advanced prostate cancer. These drugs are abiraterone (Zytiga) and enzalutamide (Xtandi). Currently, both of them are approved for use after a man has failed chemotherapy with docetaxel. In addition, [...]
Sipuleucel-T (Provenge) has shown in clinical trials that it prolongs overall survival (OS) in asymptomatic or minimally symptomatic men with castrate resistant prostate cancer (CRPC). Unlike many other treatments for men with CRPC there are not any reliable biomarkers to show that it is working for any individual. There is also a lack of markers [...]
There are different methods of performing ADT; these methods include continuous or intermittent as well as differences in the actual blockade itself. Understanding the superior schedule as well as the superior combination of drugs can both delay the onset to castrate resistance as well as provide for a longer overall survival (OS). In a research [...]
On March 4, 2014 I wrote a post “Castrate Resistant Prostate Cancer- What to Do Next” (www.advancedprostatecancer.net/?p=4425). The basic theme of the post was about how difficult it is to know how to sequence the new drugs we have to treat advanced prostate cancer (metastatic castrate resistant prostate cancer aka mCRPC). In the post I [...]
Satraplatin is an oral platinum drug that is believed to bind the DNA of the cancer cell, which then prevents the cancer from being able to reproduce. Satraplatin had been tested in a phase III trial in men with metastatic castrate-resistant prostate cancer (mCRPC) who have failed chemotherapy with docetaxel. It failed because it did [...]
It has been announced by the International Strategic Cancer Alliance that a Dutch university that intends to launch global trials has purchased the Combidex technology. Combidex is a scan contrast that periodically gets discussed among prostate cancer survivors, but it has not been available for a few years. It is an injectable nanoparticle fluid (contrast) [...]
Today’s New York Times Science Times section had a very interesting article written by Tara Parker-Poe about Male breast cancer. As her opening line of the article went, “Breast cancer is not always pink.” She wrote about a photography series recently mounted that feature the faces and scars of men with breast cancer. The photos [...]
